Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (3.942.861 €): Interdisziplinäres Ausbildungsnetzwerk zur Weiterentwicklung der Organ-on-a-Chip-Technologie in Europa Hor12.11.2018 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Interdisziplinäres Ausbildungsnetzwerk zur Weiterentwicklung der Organ-on-a-Chip-Technologie in Europa
EUROoC will create a trans-European network of industrially oriented specialists fully trained in development and application of the emerging Organ-on-a-chip (OoC) technology. OoC technology is advancing at breath taking pace due to its potential impact in drug development and personalised treatments of disease. New researchers entering this field must be equipped with a multidisciplinary background ranging from biology to microfluidic chip engineering. EUROoC will offer the first complete and coherent European training program on OoC by gathering multidisciplinary participants (biologists, physicists, chemists, engineers) in a multi-sectoral network composed of 4 companies (3 SMEs), 2 regulation entities and 10 academic institutions. EUROoC will qualify the next generation of interdisciplinary scientists for all aspects of OoC development and utilisation, including understanding of commercialisation pathways and regulatory aspects. EUROoC furthermore comprises a collection of innovative research projects addressing the development of advanced OoC systems with higher physiological significance going beyond current in vitro testing. The EUROoC project will create advanced OoCs, which closely recapitulate properties of the respective organ tissues in vivo regarding cell types, microenvironment, organ-specific tissue structure and function as well as concepts for the interconnection of individual OoCs. The various OoC models to be developed comprise heart-on-a-chip, bone-on-a-chip, retina-on-a-chip, lung-on-a-chip, adipose- on-a-chip, gut-on-a-chip to liver-on-a-chip. The OoC systems will be able to monitor and analyse tissue functionality and response in situ by integrating various novel sensing elements. The OoCs developed will be pre-validated with the regulatory partners through in vitro-in vivo correlations. The research and training program planned will increase European competitiveness sustainably in this emerging key technology.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Astrazeneca UK Ltd. | ? |
| Academisch Ziekenhuis Leiden | 531.240 € |
| Bundesinstitut Fuer Risikobewertung | 252.788 € |
| Ecole Polytechnique Federale DE Lausanne | 281.277 € |
| Fraunhofer Gesellschaft ZUR Forderung DER Angewandten Forschung e. V. | 323.007 € |
| Miltenyi Biotec B.V. & Co. KG | 224.701 € |
| Miltenyi Biotec GmbH | 28.088 € |
| Naturwissenschaftliches UND Medizinisches Institut AN DER Universitaet Tuebingen | 182.569 € |
| Technische Universitaet Graz | 528.414 € |
| Universitaet Bern | 281.277 € |
| Universitatsklinikum Jena | 505.577 € |
| Universite Du Luxembourg | 256.320 € |
| Universiteit Twente | 265.620 € |
| Uppsala Universitet | 281.983 € |
Quelle: https://cordis.europa.eu/project/id/812954
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der aktuelle Stand wird auf folgender Seite wiedergegeben: Astrazeneca UK Ltd., Cambridge, Großbritannien.
